A chronic wound is a problem often encountered in medical care, especially in areas that do not have adequate health facilities. Several factors causing the injury are mechanical, chemical, electrical, or heat. Chronic inflammation and bacterial infections are two significant factors that affect the process of wound chronicity. Mitomycin-C (MMC) is widely used as intravenous, oral, or topical anti-cancer drug. Mitomycin-C that is topically administration to an injury can cause cross-linking and decrease or stop the DNA transcription process lead the injury will not reach the healing phase. Mitomycin-C works as an inhibitor of fibroblast proliferation that can inhibit wound healing process. This study aimed to investigate the effect of topical MMC administration in chronic wound animals model. Eight female Wistar rats aged 70 to 90 days and weighing between 300 to 350g were used in this study. Wound model was made in the back area with a diameter of approximately 2 cm. Rats were then divided into 2 groups. The first group as treatment group which the wound rats were compressed using sterile gauze moistened with 0.5 mg/mL of MMC for five min and rinsed with 10 mL of saline solution. The second group as control which the wound rats were compressed by using sterile gauze moistened with saline for 5 minutes. On day 3, 5, and 15, the wound profiles were observed consisting of wound diameter, necrosis, and consistency. The rat wound after MMC administration showed a slower decrease in diameter, fewer scar tissue formation, and development of necrotic tissue. In addition, the rat wound appeared as brownish-black, dry, thick chronic wounds and took longer to heal compared to those saline control. In conclusion, MMC administration inhibits the wound healing process on rat surgical wound model.